Shields, Beverley M.
Angwin, Catherine D.
Shepherd, Maggie H.
Britten, Nicky
Jones, Angus G. http://orcid.org/0000-0002-0883-7599
Sattar, Naveed http://orcid.org/0000-0002-1604-2593
Holman, Rury
Pearson, Ewan R. http://orcid.org/0000-0001-9237-8585
Hattersley, Andrew T. http://orcid.org/0000-0001-5620-473X
Funding for this research was provided by:
RCUK | Medical Research Council (MR/N00633X/1, MR/N00633X/1, MR/N00633X/1, MR/N00633X/1, MR/N00633X/1, MR/N00633X/1, MR/N00633X/1, MR/N00633X/1)
Article History
Received: 4 October 2022
Accepted: 7 November 2022
First Online: 7 December 2022
Competing interests
: N.S. is supported by a British Heart Foundation Centre of Excellence Award (RE/18/6/34217). R.H. is an Emeritus National Institute for Health Research Senior Investigator. A.H. was a Wellcome Senior Investigator (098395/Z/12/Z) and is an Emeritus Senior Investigator at the NIHR. A.H., B.S., M.S., A.G. and C.A. are supported by the NIHR Exeter Clinical Research Facility and National Institute for Health and Care Research Exeter Biomedical Research Centre. E.P. has received Honoraria from Lilly, Sanofi and Illumina. N.S. has consulted for and/or received speaker honoraria from Abbott Laboratories, Afimmune, Amgen, Astrazeneca, Boehringer Ingelheim, Eli-Lilly, Hanmi Pharmaceuticals, Janssen, MSD, Novo Nordisk, Novartis, Sanofi and Pfizer and received grant funding paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics. R.R.H. reports research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal fees from Anji Pharmaceuticals, AstraZeneca, Novartis and Novo Nordisk. The remaining authors declare no competing interests.